Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
24 Oct 2024: ABL Bio introduces platform tech to speed up developing bispecific ADCs
- ABL Bio has signed a technology transfer agreement with IntoCell, which specializes in ADC technology, to research and develop ADCs
- The agreement involves integrating IntoCell’s ADC platform technology with ABL Bio’s antibodies to enhance the development of targeted cancer treatments
- This agreement follows ABL Bio’s prior collaboration with Synaffix to develop bispecific ADCs, with ongoing non-clinical studies using Synaffix’s linker-payload technology
- ABL Bio aims to submit at least two investigational new drug (IND) applications to the U.S. FDA by the end of next year, positioning itself for leadership in the emerging bispecific ADC market
